Cancer Advisor

Prostate cancer remains one of the most widely diagnosed malignancies globally. For decades, the therapeutic roadmap has relied on a foundational paradigm: prostate cancer cells are driven by androgens. Consequently, standard care heavily prioritizes Androgen Deprivation Therapy (ADT) and next-generation androgen receptor pathway inhibitors (ARPIs). While these interventions regularly deliver impressive initial declines in tumor volume and prostate-specific antigen (PSA) markers, they inadvertently establish a high-stakes evolutionary battleground within the tumor microenvironment. By aggressively blocking the androgen axis, conventional therapies exert an intense selective pressure on malignant cells. Instead of eradicating the disease, this environment forces the cancer to adapt, mutate, and evolve. The ultimate manifestation of this survival mechanism is Lineage Plasticity, a process where common, highly treatable prostate adenocarcinoma completely changes its cellular identity, tra...

Introduction: Can Low-Dose Naltrexone (LDN) Play a Role in Cancer Treatment? Low-dose naltrexone (LDN) has emerged as one of the most discussed repurposed drugs in integrative oncology—drawing attention from researchers, clinicians, and patients seeking safer, adjunctive cancer therapies. Originally developed as a high-dose medication to treat opioid and alcohol dependence, naltrexone behaves very differently when used at much lower doses (typically 1–5 mg daily), triggering unique biological effects that may influence cancer biology. Unlike conventional chemotherapy, which directly targets rapidly dividing cells, LDN appears to work through indirect mechanisms—modulating the immune system, altering inflammatory pathways, and influencing cellular signaling involved in tumor growth. One of the most studied mechanisms involves the opioid growth factor (OGF)–opioid growth factor receptor (OGFr) axis , a regulatory pathway that plays a key role in controlling cell proliferation. By transie...